Süleyman BÜYÜKBERBER, Umut DEMİRCİ, Meltem BAYKARA, Uğur COŞKUN, Mustafa BENEKLİ

Renal hücreli kanserin karaciğer metastazında transarteryel kemoembolizasyon

Transarteryel kemoembolizasyon (TAKE) hepatosellüler kanserin palyatif tedavisinde ve kolorektal kanserin karaciğer metastazlarında başvurulan bir yöntemdir. Sistemik tedavi sonrasında ardışık uygulanan TAKE ile metastazlarında belirgin yanıt sağlanan ve uzun süreli sağkalım elde edilen metastatik renal hücreli kanser olgusu sunulmuştur. Karaciğere metastatik renal hücreli kanserde sistemik tedaviye ek olarak sitoredüksiyon sağlamak amacı ile TAKE tedavi seçeneği olabilir.

Transarterial chemoembolization of liver metastasis from renal cell carcinoma

Transarterial chemoembolization (TACE) is a method that mainly uses palliative treatment of hepatocellular carcinoma and liver metastasis from colorectal carcinoma. We reported a case who achieved an obvious response in metastases from renal cell carcinoma with sequential administered systemic treatment and TACE, in addition to a long term survival. Transarterial chemoembolization can be an optional addition to systemic treatment for cytoreduction of liver metastasis from renal cell cancer

PDF

___

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300. [CrossRef]
2. Tsui KH, Shvarts O, Smith RB, Figlin R, de Kernion JB, Belldegrun A. Renal cell carcinoma: prognostic significance of incidentally detected tumors. J Urol 2000; 163: 426-30. [CrossRef]
3. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356: 115-24. [CrossRef]
4. Sun M, Lughezzani G, Perrotte P, Karakiewicz PI. Treatment of metastatic renal cell carcinoma. Nat Rev Urol 2010; 7: 327-38. [CrossRef]
5. Zisman A, Pantuck AJ, Dorey F, Said JW, Shvarts O, Quintana D, et al. Improved prognostication of renal cell carcinoma using an integrated staging system. J Clin Oncol 2001; 19: 1649-57.
6. Coppin C, Porzsolt F, Awa A, Kumpf J, Coldman A, Wilt T. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev 2005; CD001425.
7. Heng DY, Kollmannsberger C. State-of-the-art treatment of metastatic renal cell carcinoma. Curr Oncol 2009; 16: S16-23. [CrossRef]
8. Ljungberg B, Landberg G, Alamdari FI. Factors of importance for prediction of survival in patients with metastatic renal cell carcinoma, treated with or without nephrectomy. Scand J Urol Nephrol 2000; 34: 246-51. [CrossRef]
9. Stadler WM, Huo D, George C, Yang X, Ryan CW, Karrison T, et al. Prognostic factors for survival with gemcitabine plus 5-fluorouracil based regimens for metastatic renal cancer. J Urol 2003; 170: 1141-5. [CrossRef]
10. Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Medical Research Council Renal Cancer Collaborators. Lancet 1999; 353: 14-7. [CrossRef]
11. Zini L, Capitanio U, Perrotte P, Jeldres C, Shariat SF, Arjane P, et al. Population- based assessment of survival after cytoreductive nephrectomy versus no surgery in patients with metastatic renal cell carcinoma. Urology 2009; 73: 342-6. [CrossRef]
12. Nabil M, Gruber T, Yakoub D, Ackermann H, Zangos S, Vogl TJ. Repetitive transarterial chemoembolization (TACE) of liver metastases from renal cell carcinoma: local control and survival results. Eur Radiol 2008; 18: 1456-63. [CrossRef]
13. Tawfiek ER, Bagley DH. Upper-tract transitional cell carcinoma. Urology 1997; 50: 321-9. [CrossRef]